Mail Stop 4561

	June 7, 2006

Sudhakar Kesavan
Chief Executive Officer
ICF International, Inc.
9300 Lee Highway
Fairfax, Virginia 22031

Re:	ICF International, Inc.
      Registration Statement on Form S-1
      Filed May 11, 2006
      File No. 333-134018

Dear Mr. Kesavan:

	We have reviewed your filing and have the following comments.
Where indicated, we think you should revise your document in
response
to these comments.  If you disagree, we will consider your
explanation as to why our comment is inapplicable or a revision is
unnecessary.  Please be as detailed as necessary in your
explanation.
In some of our comments, we may ask you to provide us with
supplemental information so we may better understand your
disclosure.
After reviewing this information, we may or may not raise
additional
comments.

	Please understand that the purpose of our review process is
to
assist you in your compliance with the applicable disclosure
requirements and to enhance the overall disclosure in your filing.
We look forward to working with you in these respects.  We welcome
any questions you may have about our comments or any other aspect
of
our review.  Feel free to call us at the telephone numbers listed
at
the end of this letter.

General
1. Please provide us copies of market and industry data that you
cite
or rely on in your filing.  These materials should be
appropriately
marked, dated, and refer to the page number on which they are
cited.
We note, for example, cites to the International Energy Agency and
U.S. Department of Transportation on page 2.

Prospectus Cover Page
2. We note the disclosure regarding the application to have your
common stock approved for quotation on the Nasdaq.  Please advise
us
of the basis for your belief that you will be quoted on the
Nasdaq.
Please refer to the note to Item 202 of Regulation S-K.
3. Please revise to delete the reference to "sole book-running
manager" from the cover page.  This information is more
appropriate
for the underwriting section of the prospectus or the back cover
page.

Prospectus Summary, page 1
4. The summary should provide investors with a clear, concise and
coherent "snapshot" description of the most significant aspects of
the offering.  We note that much of the information in the summary
is
repeated in, and more appropriate for, the body of the prospectus.
For example, disclosure relating to "Market Opportunity" starting
on
page 2 is repeated on page 59 through 62.  Disclosure regarding
your
competitive strengths and business strategy on pages 3-4 is
repeated
on pages 62 through 65.  Please revise to delete repetitious
disclosure.  If you wish to retain information about your market
opportunity, competitive strengths, and business strategy in the
summary, please limit the disclosure to a brief summary rather
than
the detailed disclosure you currently provide.

ICF International, Inc., page 1
5. To the extent that you retain disclosure regarding your backlog
as
of December 31, 2005, please revise to briefly describe how
backlog
is calculated.

Risk Factors, page 4
6. Please revise the risk factor at arrow one to indicate the
extent
to which your revenues are derived from contracts with the federal
government and its agencies.

Risk Factors, page 10
7. Please review your risk factor subheadings to ensure they
reflect
the risk you describe in the text.  Some of your subheadings
merely
state facts about your business.  For example, we note the heading
"Our commercial business depends on the energy sector of the
global
economy, which is highly cyclical," on page 13.  Please review and
revise subheadings to succinctly state the risks that will result
from the facts or circumstances you discuss.



Risks related to our industry

The failure by Congress to approve budgets in a timely manner for
the
federal agencies and departments we support could delay and reduce
spending and cause us to lose revenue and profit, page 10
8. Please revise to reference the impact that failure to approve a
budget timely would have on your operating results.

Unfavorable government audit results could force us to adjust
previously reported operating results, could affect future
operating
results and could subject us to a variety of penalties and
sanctions,
page 11
9. We note that government audits have been completed on your
incurred contract costs through 2001. Please advise us as to
whether
you have historically had any negative audits or any determination
by
the DCAA or other agencies that costs were improperly allocated.
If
so, please revise to provide brief disclosure in this regard.

Risks related to our business

We are dependent on contracts with U.S. federal government
agencies
and departments for the majority of our revenue and profit, page
12
10. The concluding sentence of this risk factor appears to
contradict
the first sentence of the paragraph wherein you state that you
believe one of the key elements of your success is your position
as a
prime contractor under GSA Schedule contracts and other IDIQ
contracts. Please revise to address this inconsistency or advise.

The loss of key members of our senior management team could impair
our relationships with clients and disrupt the management of our
business, page 14
11. Please revise to identify the key members of senior management
upon whom you rely.

We face intense competition from many competitors that have
greater
resources than we do, which could result in price reductions,
reduced
profitability and loss of market shares, page 16
12. Please confirm, if true, that the principal competitors whom
you
have named are representative of your competitors as a whole.


We have incurred substantial amounts of debt and expect to incur
additional debt in the future, which could substantially reduce
our
profitability, limit our ability to pursue certain business
opportunities, and reduce the value of your investment, page 18
13. Because of the length of this risk factor, please revise to
break
out the risks related to your debt both present and future under
separate risk factor sub-headings.
14. We note your statement in paragraph two that at times you
"have
not fulfilled the covenants, maintained the ratios, or complied
with
the financial tests specified in [y]our financial arrangements,"
or
have done so only marginally. Please revise, as applicable, to
disclose the ramifications of not fulfilling the covenants, or
doing
so only on a marginal basis.

Our international operations pose special and unusual risks to our
profitability and operating results, page 19
15. Please identify for us the "other foreign countries" where ICF
International performs work.

The diversity of the services we provide and the clients we serve
may
create actual, potential and perceived conflicts of interest and
conflicts of business that limit our growth and lead to liability
for
us, page 22
16. Please revise to briefly describe the internal process for
determining whether a project would create a potential or actual
conflict of interest.

Our principal investor and some members of our board of directors
may
have conflicts of interest that could hinder our ability to make
acquisitions, page 26
17. Please revise to address whether there are mechanisms in place
to
address conflicts of interest arising when the acquisition goals
of
ICF International and CMEP or FSAC are similar with respect to a
particular complementary business.
18. Please advise whether FSAC has identified any federal services
business for acquisition. We note that FSAC has earmarked $120
million for this purpose.

We have never operated as a public company, and fulfilling our
obligations incident to being a public company will be expensive
and
time consuming, page 26
19. Please revise to provide an estimate of the costs associated
with
being a public company.



Use of Proceeds, page 31
20. We note that you will use a portion of the proceeds from this
offering for debt repayment.  If the indebtedness to be discharged
was incurred within one year, describe the use of the proceeds of
such indebtedness.  Refer to Instruction 4 to Item 504 of
Regulation
S-K.

Capitalization, page 33
21. Please advise us why the current portion of long-term debt is
not
included in the sum of your total capitalization or revise
accordingly.

Selected consolidated financial and other data, page 38
22. Reference is made to your classification of the unusual
expense
included in EBITDA.  Since non-cash compensation is an ordinary
expense, please consider clearly stating the nature of the charge
rather than characterizing it as unusual.

Management`s Discussion and Analysis, page 41
23. The final sentence of your introductory paragraph suggests
that
there may be other factors possibly affecting operating results of
which you are presently aware, but have not included as risk
factor
disclosure. Please advise or revise.

Liquidity and Capital Resources, page 52
24. Please revise to quantify all material short-term liquidity
requirements.  Further, provide similar disclosure regarding all
material long-term liquidity requirements.
25. We note disclosure on page 18 in the Risk Factors section,
indicating that your financing arrangements require you to
maintain
specified financial ratios and tests. Please expand your
disclosure
to briefly describe these financial ratios and tests.  Also
indicate
whether you are currently in compliance with those ratios and
tests.

Cash and net working capital, page 52
26. We note your disclosure that as part of your acquisitions of
Synergy and Caliber, you acquired receivables which were higher in
terms of days sales outstanding than the company as a whole.  Tell
us
what consideration you have given to discussing the potential
credit
risk related to these receivables and how management intends to
address any increased risk.


Cash flow, page 52
27. Please revise to clarify why you experienced a decrease in
deferred revenue and accrued expenses in fiscal 2004.

Credit Agreement, page 53
28. The last paragraph on page 53 indicates that you expect to
enter
into new credit facilities after completion of this offering.
Please
revise to clarify how you will finance working capital needs and
fund
future acquisitions if you are unsuccessful in securing new credit
facilities on favorable terms.
29. Refer to the table at the top of page 54.  Please revise to
clarify whether the amounts outstanding include accrued but unpaid
interest, or if they reflect principal only.  Also, please clarify
whether the amount of term loans outstanding includes amounts
under
both the term loan maturing in 2010 and the short-term loan
maturing
in January 2007.  If so, please show those amounts separately in
the
table.

Contractual Obligations, page 54
30. Please revise, as applicable, to describe any provisions that
create, increase or accelerate obligations, or other pertinent
data
to the extent necessary for an understanding of the timing and
amount
of the contractual obligations.  Refer to Item 303(a)(5) of
Regulation S-K.
31. Please tell us why the table indicates that a portion of your
term loan will mature in less than 1 year and in 1-3 years.  We
note
disclosure on page 53 indicating that the maturity date of your
term
loan is October 2010.  Similarly, please tell us why the table
reflects two different maturity periods for the time loan.

Business

Focus on high margin projects, page 65
32. Please revise to briefly identify the basis for your
expectation
that the energy industry will be a "particularly attractive
market"
for you over the next decade.

Services and Solutions, page 66
33. Please revise to include a definition of "NEPA."



Environment and infrastructure, page 70
34. We note your statement that for more than three decades you
have
been a "leading" provider of services for the design, evaluation
and
implementation of environmental polices and projects across all
environmental media. Please revise to indicate the measure whereby
you determined that you are a leading provider, whether by
revenues
or some other means.  Also, provide independent third-party
support
for your assertion that you are a leader in this field.

Corporate Governance and Board Committees, page 80
35. Please provide additional disclosure regarding each committee
to
discuss the frequency with which each will have meetings.

Compensation Committee Interlocks and Insider Participation, page
81
36. Please revise to identify the entity for which Peter Schulte
serves as a member of the board of directors or compensation
committee.  Identify any other executive officers of that entity
that
serve as members of ICF`s board of directors.

Executive Compensation

Summary Compensation Table, page 83
37. We note disclosure on page 85 indicating that on October 1,
2005
you entered into an employment agreement under which Mr. Croan
would
receive a base salary of $194,000 per year.  Please confirm, if
true,
that Mr. Croan did not receive salary and bonus of at least
$100,000
for the year ended December 31, 2005, such that it was appropriate
not to include disclosure pursuant to Item 402 of Regulation S-K
identifying Mr. Croan as one of the most highly compensated
executive
officers for that year.
38. Please revise the table to clarify, by footnote or otherwise,
whether amounts paid as bonus were paid under the terms of the
Employee Annual Incentive Compensation Pool Plan, or whether the
bonus amounts were paid at the discretion of the board of
directors
or the compensation committee.
39. Please revise the summary compensation table to reflect shares
underlying all options granted to the named executive officers in
each of the three fiscal years shown.  For example, we note that
the
option grants table on page 84 indicates that you granted options
to
Mr. Stewart and Ms. Glover in 2005; however, the shares underlying
those options do not appear in the summary compensation table.


2005 Restricted Stock Plan, page 86
40. Please revise to clarify whether any shares of restricted
stock
have been granted to date under the plan.  If so, please revise
the
summary compensation table on page 83 to reflect those shares, if
appropriate.

Principal and selling stockholders, page 92
41. Please identify all selling shareholders who are registered
broker-dealers or affiliates of broker dealers.  Additionally,
tell
us if the broker-dealer received the securities as underwriting
compensation.  Please note, a registration statement registering
the
resale of shares being offered by broker-dealers must identify the
broker dealers as underwriters if the shares were not issued as
underwriting compensation.
42. We note that you have included "Entities Affiliated with CM
Equity Partners, L.P." in your selling shareholder table. This
aggregate disclosure does not appear consistent with the
requirement
of Item 507 of Regulation S-K, which states that "each" selling
shareholder be named, and that the attendant disclosure with
respect
to share ownership be broken out. Please revise to provide all
disclosure required by Item 507 of Regulation S-K.
43. We note disclosure in footnote (1) indicating that Messrs.
Shulte, Jacks, and Hopkins beneficially own the shares held by
affiliates of CM Equity Partners, L.P.  Please revise the table to
separately identify these three individuals and to show the full
amount of their beneficial ownership.  Disclaimers of beneficial
ownership may be disclosed by footnotes to the table.

Underwriting, page 104
44. At the conclusion of the first paragraph you describe the
underwriting agreement as subject to terms and conditions.  Please
provide to us a draft copy of the underwriting agreement, so that
we
may review in more detail the terms and conditions.
45. We note the discussion beginning on page 107 regarding the
offering of stock in foreign countries.  Please tell us whether
this
public offering is part of a global offering and revise your
disclosure as appropriate.







Financial Statements - ICF International, Inc, and Subsidiaries

General
46. Update your financial statements pursuant to 3-12 of
Regulation
S-X.

Consolidated Statements of Operations, page F-4
47. Please advise us how your presentation of non-cash
compensation
as a separate line item on the face of your statement of
operations
complies with the guidance in SAB Topic 14F or revise accordingly.

Note B - Summary of Significant Accounting Policies

Revenue Recognition, page F-8
48. Further explain how you determine the pro-rata portion of
fixed
fees to be recognized on cost-type contracts and tell us if the
referenced probable and estimable fees are billable under the
contractual terms.  Also, we note that actual and anticipated
awards
are considered in estimating revenues.  Clarify your basis for the
consideration of award fees prior to the time in which they are
triggered under the terms of the contract.
49. We note that under certain circumstances you may proceed with
work prior to signing formal contract documents.  Please clarify
how
you determine persuasive evidence of an arrangement exists in
these
circumstances under SAB Topic 13A2.  Advise us of your customary
business practices as it relates to these customers and how your
policy is consistent with those practices. Lastly, explain what
legal
rights you have to payment in situations where services have been
performed without a contract.

Stock-based compensation plan, page F-11
50. Tell us how you determined the fair value of the Company`s
stock
for purposes of calculating the charge to compensation expense on
the
date the vesting of all outstanding unvested options was
accelerated.
Include in your response a discussion of the valuation methodology
as
well as the significant assumptions used by the Company in
determining the fair value.   In addition tell us what
consideration
was given to the pending initial public offering and how that
factored into your valuation.





Note C - Acquisitions, page F-13
51. Explain to us how you have considered the disclosure
requirements
of paragraph 51(b) of SFAS 141 as it relates to goodwill acquired
as
part of the acquisition transactions.
52. Tell us how you have complied with the disclosure requirements
in
paragraph 51(d) of SFAS 141 as it relates to the stock issued in
connection with the Synergy, Inc. acquisition.  Include in your
response the number of shares issued and a discussion of the
valuation methodology as well as the significant assumptions used
in
determining the fair value.
53. Based on your discussion here it appears that you have
concluded
that any earnout payments resulting from your acquisition of
Caliber
Associates, Inc should be accounted for as an adjustment to the
purchase price.  In a supplemental response to us, please explain
how
you have considered the guidance in EITF 95-8 in determining the
appropriate accounting treatment.  Specifically address whether
the
former owners to which payment is being made are current employees
of
the Company, and if so whether any continuing employment criteria
must be met in order for the employee to be eligible to receive
the
payment.

Note N - Stockholders` Equity, page F-25
54. For equity instruments granted during the 12 months prior to
the
date of the most recent balance sheet included in the registration
statement, tell us what consideration was given to disclosing in
the
notes to the financial statements the following:
* For each grant date, disclose the number of options or shares
granted, the exercise price, the fair value of the common stock,
and
the intrinsic value, if any, per option;
* Disclose whether the valuation used to determine the fair value
of
the equity instruments was contemporaneous or retrospective;
* Indicate whether or not the valuation was performed by an
unrelated
third party.

Financial Statements - December 31, 2004 Audited Financial
Statements
of Caliber Associates, Inc.

Report of Independent Accountants, page F-28
55. Please have your auditors revise their report to include the
city
and state of the office issuing the opinion.


Financial Statements - September 30, 2005 Unaudited Financial
Statements of Caliber Associates, Inc.
56. We note the reference at the bottom of your financial
statements
to the independent accountants` review report.  Please tell us
where
this report has been included in your filing or include it in your
next amendment.

Part II

Item 15.  Recent Sales of Unregistered Securities
57. Please revise to identify the exemption relied upon for each
issuance and to provide a description of the facts that support
your
use of each such exemption.  We note the general disclosure at the
end of this section, however, the specific exemption relied upon
for
each transaction is not clear.
58. Please revise to indicate the type and amount of consideration
received in each in connection with the issuance of options.

Item 16.  Exhibits
59. Please file all remaining exhibits as soon as possible. Upon
review, we may have further comments.  If you are not prepared to
file the legal opinion with your next amendment, please provide a
draft of the opinion for us to review.

      As appropriate, please amend your registration statement in
response to these comments.  You may wish to provide us with
marked
copies of the amendment to expedite our review.  Please furnish a
cover letter with your amendment that keys your responses to our
comments and provides any requested supplemental information.
Detailed cover letters greatly facilitate our review.  Please
understand that we may have additional comments after reviewing
your
amendment and responses to our comments.

      We urge all persons who are responsible for the accuracy and
adequacy of the disclosure in the filings reviewed by the staff to
be
certain that they have provided all information investors require
for
an informed decision.  Since the company and its management are in
possession of all facts relating to a company`s disclosure, they
are
responsible for the accuracy and adequacy of the disclosures they
have made.

	Notwithstanding our comments, in the event the company
requests
acceleration of the effective date of the pending registration
statement, it should furnish a letter, at the time of such
request,
acknowledging that:

* should the Commission or the staff, acting pursuant to delegated
authority, declare the filing effective, it does not foreclose the
Commission from taking any action with respect to the filing;

* the action of the Commission or the staff, acting pursuant to
delegated authority, in declaring the filing effective, does not
relieve the company from its full responsibility for the adequacy
and
accuracy of the disclosure in the filing; and

* the company may not assert this action as a defense in any
proceeding initiated by the Commission or any person under the
federal securities laws of the United States.

	In addition, please be advised that the Division of
Enforcement
has access to all information you provide to the staff of the
Division of Corporation Finance in connection with our review of
your
filing or in response to our comments on your filing.

      We will consider a written request for acceleration of the
effective date of the registration statement as a confirmation of
the
fact that those requesting acceleration are aware of their
respective
responsibilities under the Securities Act of 1933 and the
Securities
Exchange Act of 1934 as they relate to the proposed public
offering
of the securities specified in the above registration statement.
We
will act on the request and, pursuant to delegated authority,
grant
acceleration of the effective date.

      We direct your attention to Rules 460 and 461 regarding
requesting acceleration of a registration statement.  Please allow
adequate time after the filing of any amendment for further review
before submitting a request for acceleration.  Please provide this
request at least two business days in advance of the requested
effective date.

	You may contact Robert Telewicz, Accountant, at (202) 551-
3438
or Cicely LaMothe, Accounting Branch Chief, at (202) 551-3413 if
you
have questions regarding comments on the financial statements and
related matters.  Please contact Paul Fischer, Attorney-Advisor,
at
(202) 551-3415 or me at (202) 551-3780 with any other questions.



      Sincerely,



      Karen J. Garnett
      Assistant Director


cc:	James J. Maiwurm, Esq. (via facsimile)
      Squire, Sanders & Dempsey LLP










Mr. Sudhakar Kesavan
ICF International, Inc.
June 7, 2006
Page 1